In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The market's underestimating how well each of these companies should be able to capitalize on their opportunities.

Sweeping layoffs, funding freezes and executive orders have provoked outcry among federal researchers and their university partners, who fear that science itself is under siege.

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Right now, your puberty will have you end up in a boy body, but there’s these different options. If you want to, we can pause ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

British physician and microbiologist Alexander Fleming, discoverer of penicillin nearly 100 years ago, was the first to warn ...